Dacheng CSI All Share Health Care Equipment and Services ETF

01833

510660

589720

512010

516610

513120

159929

CICC has initiated coverage on PA GOODDOCTORwith an Outperform rating and a target price of HKD14.2. The report highlights the company's strategic transformation in healthcare and elderly care, achieving full-year profitability in 2024 and positive operating profit in 2025. CICC expects significant profit growth driven by AI enhancements and operational efficiencies, forecasting EPS of RMB0.2 and RMB0.29 for 2026 and 2027, respectively, with a CAGR of 28.3% from 2025 to 2027.

AASTOCKS News

PA GOODDOCTOR

ChinaAMC SSE Health Care ETF Initiating Fund

Guotai SSE STAR Brand Name Drug ETF

E Fund CSI 300 Health Care ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal 800 Health Care ETF

CICC

CICC Initiates PA GOODDOCTOR  with Outperform Rating, TP HKD14.2

00241

Alibaba Health reported a 12% revenue increase to RMB34.26B and a 35.2% rise in net profit to RMB1.94B, driven by direct sales, digital services, and new medical AI models. CFO Tu Yanwu has resigned, with no details on succession provided, raising concerns about leadership risk. The company will pay a final special dividend by reducing its share premium account balance.

TradingView

ALI HEALTH

Key facts: Alibaba Health 34.26B rev; net +35% to 1.94B; CFO exits; dividend via premium

ALI HEALTHhas proposed to reduce its share premium by approximately RMB10 billion to fund a total dividend of RMB19.47 cents per share, which includes a final dividend of RMB5.95 cents and a special dividend of RMB13.52 cents. This decision comes as the company faces insufficient contributed surplus for distribution as of March 31, 2026. The reduction will allow the company to offset accumulated losses and distribute funds to shareholders.

ALI HEALTH Proposes to Reduce RMB10B Share Premium to Fund Dividend

ALI HEALTHreported a net profit of RMB1.94 billion for the year ending March 31, 2026, marking a 35.2% increase year-on-year. Revenue rose to RMB34.255 billion, up 12% YoY, with an EPS of RMB12.02 cents. The company declared a total dividend of RMB19.47 cents, which includes a final dividend of RMB5.95 cents and a special dividend of RMB13.52 cents.

ALI HEALTH Annual Net Profit RMB1.94B, Up 35.2% YoY; Final & Spec. Div. Total RMB19.47 Cents

159898

159883

562600

Duno Health, Inc. has launched a new daily supplement called Youth & Vitality, formulated with NAD+ precursors and essential vitamins to support cellular renewal and overall health. The supplement aims to combat aging-related issues by boosting NAD+ levels, reducing homocysteine, and promoting cardiovascular and neuroprotection benefits. It includes nicotinamide and key B vitamins, which have been clinically tested for safety and effectiveness. The product is designed for individuals approaching 50, with a promotional offer for blood testing to measure effectiveness.

prnewswire

China Merchants CSI All Share Medical Apparatus and Instruments ETF

SPDR S&P Health Equip

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

iShares US Medical Devices

SPDR S&P Health

ChinaAMC CSI All Share Health Care Devices ETF

iShares US Healthcare Providers

10:00 ETDuno Health launches the Youth & Vitality Daily Supplement

00570

516930

588130

Yesterday's closing price for China Traditional Chinese Medicine rose slightly by 1.19%, with a trading volume of approximately HKD 92 million, which is a slight increase compared to usual, reflecting the market's attention to its mid-term development prospects. The MACD daily line has not yet formed a clear strong bullish signal, but the latest dynamics in the electronic chemical pharmaceutical sector provide good visibility for it. Under the influence of news, the government's support for the traditional Chinese medicine industry is evident. With the continuous expansion of domestic healthcare demand and the increasing awareness of healthy living, the demand potential in the traditional Chinese medicine market is gradually being released. The company is further enhancing its market competitiveness through continuous research and development, innovation initiatives, and the expansion of its market network. Technically, the stock price trend remains stable above the mid-line trend level, reflecting that short-term positions are still primarily focused on position management. As market sentiment gradually recovers, if downward resistance diminishes, we can expect more significant liquidity changes and a positive drive for the market to refocus on the traditional Chinese medicine concept. The short-term trend is positively referenced, especially with the support of favorable industry prospects, traditional Chinese medicine concept stocks are not afraid of short-term market fluctuations. Caution is needed regarding the impact of the board's substantive decisions on stock prices, as well as the potential chain reaction from important economic indicators exceeding expectations. This article provides only technical analysis and market information for reference and does not constitute any investment advice. The market carries uncertainties, and investors should make independent decisions based on their own circumstances

Technical Forecast

TRAD CHI MED

Minsheng Royal CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

GF CSI All Share Health Care ETF

Penghua CSI HK Connect Health Care Composite ETF

Guotai CSI Bio-medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

E Fund CSI HK Equities Medical and Health Integration ETF

GX CN MEDTECH

E Fund Hang Seng SCHK Innovative Drug ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Pre-market trend | China Traditional Chinese Medicine (0570.HK) slightly warmed up on May 7, is there a hint of spring for the TCM concept?

AGEN

CS精准医

INGN

516820

159849

In the field of life sciences, innovation is crucial, but many companies continue to rely on inefficient workflows and manual tasks that consume valuable time. AINGENS CEO and founder Ome Ogbru, PharmD, highlights that the issue lies not in a lack of intelligence, but rather in the ineffective processes that are in place. These inefficiencies hinder progress and hinder experts from performing efficiently.

Unusual Whales

Agenus

Inogen

First Trust NYSE Arca Biotech Index Fd

ICBCCS SSE STAR Biology and Medicine ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

Invesco Biotechnology & Genome ETF

E Fund CSI Biotechnology Theme ETF

Ping An CSI Medicine and Medical Device Innovation ETF

VanEck Biotech ETF

Penghua SSE STAR Biology and Medicine ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

ALPS Medical Breakthrough

China Southern Hang Seng Biotech ETF(QDII)

ChinaAMC CSI Biotechnology Theme ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Tianhong CNI BIOMEDICINE ETF

China Merchants CSI Biotechnology Theme ETF

Disrupting Scientific Friction: How Ome Ogbru Uses AI to Free Real Science

00874

Guangzhou Baiyunshan Pharmaceutical Holdings Company (HK:0874) announced that its ninth board's term is ending, and shareholders will vote on a new tenth board at the 2025 annual general meeting. The proposed board will consist of eleven directors, including ten non-employee representatives and one employee representative. The company has nominated ten candidates, focusing on governance continuity and compliance with Hong Kong listing rules. If approved, each director will serve a three-year term. The company operates in the pharmaceutical industry, manufacturing and distributing medicines and healthcare products.

Tip Ranks

BAIYUNSHAN PH

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

GYBYS

Guangzhou Baiyunshan Pharma Sets Vote on New Three-Year Board Line-Up

MNDR

002826

Mobile-health Network Solutions (NASDAQ:MNDR) shares surged 21.30% on Wednesday following a non-binding $119 million MOU with Hector Capital Holdings aimed at acquiring BIMA and M&M Helix to expand its AI-powered healthcare services in Asia and Africa. The deal is contingent on due diligence and regulatory approvals. The broader market also supported this rise, with the Nasdaq up 1.23% and the S&P 500 up 0.81%. MNDR operates the MaNaDr platform, focusing on telemedicine and related services, primarily generating revenue from Singapore.

benzinga_article

Mobile-Health Network Solutions

TIBET AIM PHARM

iShares Global Healthcare

iShares Biotechnology ETF

Health Care Select Sector SPDR

VG Health

Nasdaq

NASDAQ Composite Index

S&P 500

Why Is Mobile-health Network Stock Soaring Wednesday?

02609

At yesterday's close, BAYZED HEALTH had a trading volume of approximately HKD 45.49 million, showing relatively active performance among small and mid-cap medical stocks. The MACD daily line has shown bullish signals above the zero axis, and the short-term moving averages are turning upwards, which is typically interpreted by the market as a confirmation signal of a phase upward trend, indicating that buying power is quietly recovering. Recently, BAYZED HEALTH's performance has gradually emerged from the bottom consolidation range, with moderate volume expansion indicating that funds are positioning at lower levels. On the news front, the Hong Kong stock market's pharmaceutical sector has recently shown a divergence in performance, with Innovent Biologics surging 6.01% yesterday, and 3SBio rising 4.14%, while the innovative drug sub-sector has attracted active capital. Leading CXOs like BeiGene and WuXi Biologics have shown relatively weak performance, with clear rotation characteristics within the sector. As a participant in the healthcare services field, BAYZED HEALTH benefits from the long-term logic of sustained growth in domestic healthcare demand. In April, the PMI service index was 49.6%, slightly below the boom-bust line, but healthcare services, as a necessity, are relatively less affected by economic cycle fluctuations. At the same time, the Federal Reserve's policy tone of maintaining interest rates has somewhat alleviated the pressure of capital outflow, which is beneficial for stabilizing the valuations of small and mid-cap stocks in the Hong Kong market. From a technical perspective, the bullish signals above the zero axis provide directional reference, but the current trading volume level remains moderate. To further confirm the upward trend, sustained volume support is needed. Today, attention should be paid to the overall capital flow in the pharmaceutical sector and whether this stock can maintain active buying interest during the trading session. The divergent performance of the innovative drug and healthcare services sub-sectors will influence the direction of capital allocation

BAYZED HEALTH

INNOVENT BIO

3SBIO

BeOne Medicines

BEONE MEDICINES

Beigene

WUXI BIO

Sunshine Guojian Pharmaceutical

WuXi Biologics

Pre-market trend | BAYZED HEALTH (2609.HK) Short-term bulls emerge on April 30, is there an undercurrent in the healthcare sector?

Dacheng CSI All Share Health Care Equipment and Services ETF(516610.SH)

CICC Initiates PA GOODDOCTOR with Outperform Rating, TP HKD14.2